Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study
Real-world experience supports the role of cefiderocol as a valuable option for GNBIs, with no clinical advantage of combination therapy over monotherapy. Notably, NDM-producing infections and use of cefiderocol as salvage therapy are associated with poor outcomes, highlighting the need for optimised treatment strategies.
Authors
- Roberto Cauda
- Vincenzo Scaglione (ORCID: https://orcid.org/0000-0002-2911-2255)
- Mauro Codeluppi (ORCID: https://orcid.org/0000-0001-7733-463X)
- G Tagliaferri (ORCID: https://orcid.org/0000-0003-1097-2746)
- Caterina Monari (ORCID: https://orcid.org/0000-0003-2622-0573)
- Silvia Garilli
- Federica Borghi
- Chiara Iaria (ORCID: https://orcid.org/0000-0002-5477-9887)
- Marco Rizzi (ORCID: https://orcid.org/0000-0002-2081-8542)
- Michele Bartoletti (ORCID: https://orcid.org/0000-0002-9631-5693)
- Nicolò Rossi (ORCID: https://orcid.org/0000-0003-4895-4789)
- Benedetta Varisco
- Luisa Frallonardo (ORCID: https://orcid.org/0009-0001-3897-9678)
- Alessandra Mularoni (ORCID: https://orcid.org/0000-0001-8612-5581)
- Paolo Fusco (ORCID: https://orcid.org/0000-0002-3949-4293)
- Stefano Rusconi (ORCID: https://orcid.org/0000-0002-0375-9990)
- Giuseppe Pipitone (ORCID: https://orcid.org/0000-0002-3408-4877)
- Marianna Meschiari (ORCID: https://orcid.org/0000-0002-1254-9995)
- Laura Timelli (ORCID: https://orcid.org/0000-0003-2306-0260)
- Nicola Coppola (ORCID: https://orcid.org/0009-0000-3202-5489)
- Linda Bussini (ORCID: https://orcid.org/0000-0001-9956-6458)
- Matteo Augello (ORCID: https://orcid.org/0000-0002-1031-9504)
- Raffaele Bruno (ORCID: https://orcid.org/0000-0002-0235-9207)
- Carlo Torti (ORCID: https://orcid.org/0000-0001-7631-5453)
- Marco Franzetti (ORCID: https://orcid.org/0000-0002-6203-7584)
- Giulia Marchetti (ORCID: https://orcid.org/0000-0002-4498-4828)
- Stefania Piconi
- Paolo Bonfanti (ORCID: https://orcid.org/0000-0001-7289-8823)
- Annalisa Saracino (ORCID: https://orcid.org/0000-0001-9558-208X)
- Cristina Mussini (ORCID: https://orcid.org/0000-0002-6615-4198)
- Gianni Gattuso (ORCID: https://orcid.org/0009-0004-5847-8186)
- Maurizio Sanguinetti (ORCID: https://orcid.org/0000-0002-9780-7059)
- Francesca Di Bartolomeo
- Andrea Cona (ORCID: https://orcid.org/0000-0002-2084-6535)
- Marco Visicaro
- Salvatore Casari
- Anna Maria Cattelan
Institutions
- University of Modena and Reggio Emilia (IT)
- AOL (United States) (US)
- University of Padua (IT)
- University of Milan (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Agostino Gemelli University Polyclinic (IT)
- Magna Graecia University (IT)
- Ospedale Papa Giovanni XXIII (IT)
- Ospedale San Paolo (IT)
- Alessandro Manzoni Hospital (IT)
- Guglielmo da Saliceto Hospital (IT)
- Azienda di Rilievo Nazionale ed Alta Specializzazione (IT)
- Policlinico San Matteo Fondazione (IT)
- University of the Sacred Heart (JP)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Azienda Ospedaliera Ospedale Civile di Legnano (IT)
- IRCCS Humanitas Research Hospital (IT)
- Azienda Ospedaliera Carlo Poma (IT)
- Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IT)
- University of Bari Aldo Moro (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1016/j.ijid.2025.108305
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission